Healthcare Blockchain — Salud Capital Research

01 Executive Thesis

The Decentralized Medicine Inflection Point

Healthcare is the world's largest industry and also its most data-inefficient. Nearly $1.2 trillion in health data sits locked in siloed, incompatible systems annually — costing the global system upwards of $350 billion in unnecessary administrative friction, drug counterfeiting, failed clinical trials, and patient safety errors. Blockchain offers a structurally different architecture: shared, immutable, permissioned ledgers that allow data to move frictionlessly between institutions while preserving privacy, provenance, and consent.

What was a pilot-project era through 2022 has matured into an institutional adoption phase. Over 72% of healthcare organizations globally are now investing in digital transformation that includes blockchain components. Enterprise consortiums backed by the largest payers, providers, and pharma companies are in production. A parallel and faster-moving DeSci (Decentralized Science) layer has emerged as a Web3-native funding and IP mechanism that is routing around both traditional pharma and traditional academic publishing. The two currents — enterprise and DeSci — represent distinct risk/reward profiles and together define the full opportunity set.

Salud Capital's thesis is Overweight on the healthcare blockchain sector as a thematic exposure with three catalysts converging in 2026: (1) stablecoins entering production for international medical transactions, (2) regulatory clarity post-GENIUS Act enabling tokenized IP markets, and (3) NIH funding collapse accelerating demand for DeSci alternatives. This report maps every material project across five verticals and provides an investment framework.

Key Investment Insight: The sector is bifurcating into two distinct investment archetypes: (A) Enterprise / Permissioned Blockchain — low volatility, institutional backing, revenue-generating, accessible through equity in public health systems or private consortium stakes; and (B) DeSci / Token-Native Protocols — high volatility, early-stage, addressable via native tokens with asymmetric upside. Both merit allocation but require separate risk frameworks.

02 Market Architecture

Five Verticals Defining the Landscape

The healthcare blockchain ecosystem is not monolithic. It organizes into five distinct verticals, each with different technology stacks, regulatory regimes, business models, and maturity levels. Understanding which vertical a project occupies is the first step in any investment evaluation.

🏥

Electronic Health Records (EHR)

Decentralized patient record storage, identity management, cross-institution data sharing, and consent management. Core use case for permissioned blockchain in healthcare systems.

💊

Pharma Supply Chain

Drug provenance, anti-counterfeiting, chain-of-custody from manufacturer to patient, compliance with DSCSA (Drug Supply Chain Security Act). Most commercially mature vertical.

🧬

Genomics & Bio-Data

Patient-owned genomic data vaults, privacy-preserving sequencing, researcher marketplaces, and tokenized royalties for DNA contributors. Fastest-growing DeSci sub-sector.

🔬

DeSci / Research Funding

BioDAOs, IP-NFTs, tokenized clinical trial funding, and open-access publishing. Web3-native alternative to NIH/pharma funding channels with quadratic voting and community governance.

💳

Claims & Administration

Prior authorization, payer-to-payer data exchange, billing reconciliation, credential verification, and provider directories. Target of the largest enterprise consortiums.

🌍

Global Health & Telehealth

Cross-border medical payments, stablecoin-denominated care transactions, vaccine tracking in low-income regions, and decentralized telehealth platforms. High social impact, emerging market focus.

Technology Split: Private/permissioned blockchains (Hyperledger Fabric, R3 Corda) dominate enterprise deployments with 54% of 2023 installations — preferred for HIPAA/GDPR compliance. Public blockchains (Ethereum, Solana) anchor the DeSci layer where token incentives and open access are design requirements.

03 Enterprise & Institutional Players

Permissioned Blockchain — The Institutional Layer

Enterprise healthcare blockchain is characterized by consortium models, permissioned ledgers, and backing from incumbent healthcare conglomerates. These are not speculative plays — they are infrastructure being built inside the existing system, with revenue, contracts, and regulatory relationships already in place.

Enterprise / Claims & Admin

Avaneer Health

Payer-to-Payer Data Exchange, Prior Auth, Eligibility

Grown out of the Health Utility Network, Avaneer secured $50M in seed funding from Aetna, Anthem, Cleveland Clinic, HCSC, IBM, PNC, and Sentara. Built on Hyperledger Fabric + HL7 FHIR, it targets the administrative cost layer — prior authorizations, real-time eligibility checks, and payer-to-payer data sharing. CEO Stuart Hanson (fmr. Change Healthcare) is positioning Avaneer as the "last mile" interoperability layer for US healthcare. Nationwide network buildout ongoing as of 2025.

$50M Seed Hyperledger Fabric Private / Permissioned

Enterprise / EHR & Cybersecurity

Guardtime

KSI Blockchain — National Health Infrastructure

Estonia's national health system has been running on Guardtime's Keyless Signature Infrastructure (KSI) blockchain for years — one of the most advanced sovereign blockchain health deployments in the world. In 2025 Guardtime continues active vaccine tracking, EHR exchange, and patient consent management. Additional partnerships include UAE private healthcare for data privacy, and a Verizon Enterprise Solutions deployment of KSI platform services. Their "Real World Data Engine" enables pharmaceutical analytics without exposing sensitive patient records — acting as an honest broker between data owners and researchers.

Nation-Scale KSI Blockchain Estonia / UAE

Enterprise / Pharma Supply Chain

Chronicled / MediLedger

Pharmaceutical Chain-of-Custody & Anti-Counterfeiting

Chronicled is the operator of MediLedger, the industry's leading pharmaceutical blockchain network, launched in 2017 ahead of the US Drug Supply Chain Security Act (DSCSA) compliance mandate. Works with major pharma companies and distributors including Cardinal Health. The network demonstrates chain of custody from manufacturer to pharmacy — combating drug trafficking and counterfeiting. Law enforcement can review suspicious supply chain anomalies in real-time. MediLedger represents the pharma industry's best-case example of permissioned blockchain achieving production scale.

DSCSA Compliant Permissioned Cardinal Health Partner

Enterprise / EHR + Analytics

Patientory

HIPAA-Compliant Health Data Exchange, EHR Integration

Patientory connects patients, providers, and payers on a decentralized platform that integrates with Epic and Cerner via its Neith Analytics dashboard. The PTOYMatrix blockchain enables HIPAA-compliant data transfers across healthcare institutions. By 2025, Patientory expanded to support over 2 million patient records, achieving 40% year-over-year user adoption growth. The platform represents a "single source of truth" model, allowing medical professionals to access verified patient data with complete audit trails. Notably one of the few healthcare blockchain projects with a publicly traded native token (PTOY).

2M+ Records Epic/Cerner Integration PTOY Token

Enterprise / Data Exchange

Hashed Health

Healthcare Blockchain Ecosystem Development

Nashville-based Hashed Health operates as both a blockchain venture studio and protocol developer for healthcare. In 2025, it launched a new blockchain network version with 45% faster transaction processing and onboarded 10 new healthcare provider partners. Hashed Health's approach focuses on reducing pharmaceutical supply chain fraud while building credential verification tools for providers. Their ProCredEx subsidiary developed a decentralized credentialing ledger — one of the most commercially relevant B2B applications — streamlining what is traditionally a months-long manual verification process.

45% Faster TPS Venture Studio Credentialing Focus

Enterprise / Clinical Trials

Embleema

Decentralized Clinical Trial Analytics

Embleema operates at the intersection of clinical research and patient consent — a digital trial and regulatory analytics platform designed to accelerate drug development timelines. The platform secures participants' digital consent for data aggregation, which is then stored immutably on blockchain. Through the Virtual Studies Suite, Embleema enables remote patient participation in clinical trials, expanding the geographic diversity of trial populations and potentially cutting enrollment timelines by 30–40%. The platform also allows patients to selectively monetize their health data with research institutions through transparent audit trails.

Regulatory Analytics Virtual Trials Data Monetization

Enterprise / AI + Blockchain

Robomed

AI-Powered Smart Contract Care Delivery

Robomed represents a structurally differentiated model — combining blockchain smart contracts with AI, chatbots, wearable diagnostics, and telemedicine into a unified patient care system. The Panacea platform uses smart contracts to incentivize patient adherence to care protocols, creating measurable health outcomes that can be tracked and rewarded on-chain. Blockchain securely aggregates data from wearables and telemedicine sessions, sharing it with care teams in real time. The model has traction in markets where fee-for-service is inefficient and value-based care contracts are difficult to enforce.

AI + Blockchain Smart Contracts Value-Based Care

Enterprise / EHR

Medicalchain

Patient-Controlled Medical Records & Telehealth

UK-headquartered Medicalchain creates what they describe as a "single source of truth" for patient records — a permissioned ledger that allows medical professionals to access verified data while improving coordination between clinics and hospitals. The platform enables patients to share records selectively with providers, researchers, and insurers while maintaining full audit visibility. Medicalchain also runs a telehealth layer, allowing patients to consult physicians remotely with in-session health record access. The UK NHS relationship provides a meaningful institutional credentialing backstop.

UK-Based NHS Adjacent Telehealth Integration

04 DeSci — Decentralized Science Layer

The Web3-Native Research Revolution

Decentralized Science (DeSci) is the fastest-evolving layer of the healthcare blockchain thesis. It uses Web3 primitives — DAOs, NFTs, tokens, and smart contracts — to replace traditional research funding gatekeepers (NIH, pharma companies, academic publishers) with open, community-governed alternatives. The catalyst accelerating DeSci in 2025–2026 is structural: the NIH had over 7,800 grants cancelled or suspended in 2025, representing roughly $3 billion in unspent committed funds, and the White House proposed a ~40% budget cut — creating existential demand for alternative research funding rails.

Critical Catalyst — NIH Funding Collapse: NIH success rates for early-stage investigators dropped from 26% (2024) to 19% (2025). The National Cancer Institute's payline fell from 1-in-10 to 1-in-25 funded applications. NIH eliminated transparent paylines at all 27 institutes in January 2026. This collapse is routing desperate researchers toward DeSci infrastructure at an accelerating rate — a structural tailwind that may persist for years.

DeSci / IP Infrastructure

Molecule Protocol

Tokenized IP Marketplace for Drug Development

Molecule is the foundational IP infrastructure of DeSci. It enables researchers to tokenize drug development intellectual property into IP-NFTs — fractional, tradeable representations of early-stage biotech IP. Backed by $7M from a16z, Molecule connects over 500 institutions via tokenized pipelines and rewards contributors with 20% of royalties from AI-vetted drug candidates. Its Bio.xyz incubator program spun out VitaDAO, HairDAO, CryoDAO, and others. Molecule also launched pump.science — a citizen science platform where users fund longevity experiments (tested on C. elegans worms at Ora Biomedical) and own the resulting IP. In rare disease trials the platform demonstrated two therapies commercialized within 18 months.

$7M a16z IP-NFT Standard 500+ Institutions

DeSci / BioDAO Infrastructure

Bio Protocol (BIO)

Y Combinator for On-Chain Science — BioDAO OS

Bio Protocol is the "operating system" of DeSci — a management and liquidity protocol that provides modular infrastructure for launching specialized BioDAOs. Founded by Molecule's Paul Kohlhaas, it provides up to 100,000 USDC in seed funding per BioDAO with 18-week milestone-gated tranches. The BioDAO network has collectively raised $30.3M for research, with $7.2M deployed. Binance Labs made its first DeSci investment in Bio Protocol in November 2024. BIO's circulating market cap is ~$943M, fully diluted at ~$2.4B. The ecosystem spans longevity, women's health, brain health, synthetic biology, and cryogenic medicine. Roadmap includes BioDAO Launchpad v1, hundreds of new patient communities, and BIO research AI agents.

$943M Mkt Cap Binance Labs BIO Token

DeSci / Longevity DAO

VitaDAO

Longevity Science Funding & IP Ownership

VitaDAO is the most established and credentialed DeSci organization — a decentralized autonomous organization dedicated exclusively to funding longevity and healthspan research. Community members contribute capital, IP, and expertise in exchange for VITA tokens, which grant governance rights over research prioritization. VitaDAO has deployed over $10M across dozens of projects and is one of the few DeSci projects with pharma credibility — Pfizer Ventures invested $4.1M in February 2023, validating the DAO funding model at the institutional level. VitaDAO's market cap reached $180M by late 2025, and it has begun spinning out research into standalone biotech startups.

$4.1M Pfizer Investment $180M Mkt Cap VITA Token

DeSci / Women's Health

AthenaDAO

Decentralized Women's Health Research

AthenaDAO addresses one of the most chronically underfunded areas of biomedical research — women's health. Operating as a BioDAO within the Bio Protocol ecosystem and with support from AminoChain's privacy-preserving biobank infrastructure, AthenaDAO pools patient data, researcher expertise, and community capital to fund trials in areas including reproductive medicine, hormonal health, and autoimmune diseases (which disproportionately affect women). AminoChain has contributed $15M in funding for women's health DAO initiatives. AthenaDAO's governance token allows patient communities to directly vote on research priorities — a model that traditional pharma largely ignores.

$15M Backed AminoChain DAO Governance

DeSci / Genomics Vault

GenomesDAO / Nebula Genomics

Patient-Owned DNA Vaults & Genomic Data Monetization

GenomesDAO (backed by Pantera Capital's $10M round, $150M market cap) and Nebula Genomics represent the genomic data sovereignty movement. Users sequence their genomes via clinical-grade kits (30x whole genome for $299 on genomes.io) and store data in participant-owned vaults using AMD Secure Encrypted Virtualization (SEV-ES). Smart contracts automate royalties: contributors earn 15% of downstream IP from AI-driven insights, tokenized on Ethereum or Base. GenomesDAO demonstrated a Novartis pilot matching 1,200 ALS patients 28% faster than conventional recruitment. "DeSci genomic data monetization" queries surged 310% on research forums in November 2025 — a signal of massive demand-side acceleration.

$10M Pantera ZK-Proof Privacy $150M Mkt Cap

DeSci / Patient Health Data

Hippocrat (HPO)

Patient-Owned Health Data Networks On-Chain

Hippocrat is building patient-owned health data networks where individuals maintain sovereignty over all their medical records — from EHRs to wearable device data — on-chain. The platform enables immutable clinical trial records with voice biometric authentication, improving both data integrity and trial enrollment diversity by 45% (versus standard enrollment methods). Hippocrat's design centers on the concept that data generated by a patient belongs to that patient — a principle that has regulatory tailwinds as the EU's European Health Data Space (EHDS) regulation comes into force, creating legal frameworks for secondary health data use. The HPO token functions as both a governance and data access credential.

45% Enrollment Boost Voice Biometrics HPO Token

DeSci / Open Science Infrastructure

DeSci Labs

Web3 Research Publishing, IP Protection & Attribution

DeSci Labs builds the publishing and IP infrastructure layer of the DeSci stack. It enables researchers to mint Research Object NFTs (RO-NFTs) — a mechanism to timestamp and formally record scientific outputs on-chain, establishing provenance and attribution from the moment of discovery. The platform provides an open-access, immutable alternative to traditional journal publishing (which currently pockets 70% of the value from scientific work). DeSci Labs' modular research stack lets scientists build transparent scientific records without relying on Elsevier, Springer, or Nature. A 2025 Frontiers in Blockchain paper (DeScAI framework) formalized the integration of AI agents into DeSci verification systems — with DeSci Labs as a primary implementer.

RO-NFT Standard Open Access AI Integration

DeSci / Hair Loss

HairDAO

First DAO to File a Scientific Patent

HairDAO holds a unique historical distinction: it became the first decentralized autonomous organization to file a scientific patent, in December 2023 — a watershed moment for the entire DeSci thesis. Focused on alopecia and hair loss (a $9B global market), HairDAO demonstrates that patient communities can own and protect the IP they collectively fund. Operating within the Bio Protocol ecosystem, HairDAO governs research direction through token-weighted voting, with treasury deployments into early-stage compounds. Its patent filing proves that DAOs can interact with traditional IP law frameworks — a critical legal precedent for the entire sector.

First DAO Patent Bio Protocol $9B Market

05 Token & Market Data

Healthcare Blockchain Token Landscape

The investable token universe in healthcare blockchain spans enterprise-adjacent utility tokens and pure DeSci governance tokens. Valuation frameworks differ substantially between categories. Enterprise-adjacent tokens (like PTOY) should be evaluated on protocol revenue and network growth. DeSci tokens (VITA, BIO, HPO) require a venture-style framework — betting on eventual IP monetization, drug royalties, and governance value accrual.

Token / Project	Vertical	Key Backers	Mkt Cap (2025/26E)	Blockchain	Token Utility	Stage
BIO — Bio Protocol	DeSci Infrastructure	Binance Labs, Pfizer (via VitaDAO)	~$943M circ. / $2.4B FDV	Ethereum	Governance, BioDAO seeding, IP Token liquidity	Production
VITA — VitaDAO	Longevity Research	Pfizer Ventures ($4.1M), a16z-adjacent	~$180M	Ethereum	Governance, IP co-ownership, research access	Production
GENE — GenomesDAO	Genomic Data Vaults	Pantera Capital ($10M)	~$150M	Ethereum / Base	Data access, genomic royalties, governance	Growth
PTOY — Patientory	EHR / Data Exchange	Epic/Cerner partners, hospital networks	Small cap	Ethereum	Network access, data compliance fees	Growth
HPO — Hippocrat	Patient-Owned Health Data	EHDS regulatory tailwind	Emerging	Multi-chain	Data sovereignty, trial access, governance	Early
MED — Medibloc	EHR / Public Blockchain	South Korea hospital system	Mid-cap	Medibloc mainnet	Healthcare data transactions, governance	Growth

Valuation Risk: Healthcare blockchain tokens carry elevated valuation risk relative to DeFi or L1 tokens because revenue traction is nascent and regulatory uncertainty (especially HIPAA/GDPR on-chain data storage) remains unresolved. Token prices have historically tracked broader crypto cycles more than healthcare fundamentals. Size positions accordingly.

06 Regional Adoption Matrix

Global Deployment Landscape

Region	Market Share	Key Deployments	Regulatory Posture	Investment Theme
North America	Largest	Avaneer (payer network), Hashed Health, Chronicled/MediLedger (DSCSA compliance), Patientory (EHR), Change Healthcare	HIPAA compliance driving permissioned architectures. GENIUS Act opens tokenized IP. FDA pilot programs for blockchain-tracked drugs.	Enterprise consortiums, B2B SaaS-on-chain, DSCSA compliance mandates
Europe	Strong	Guardtime (Estonia national health), 800+ EU blockchain interoperability institutions, PharmaLedger consortium (EU pharma)	EU EHDS regulation creates legal secondary use framework. GDPR tensions with immutability remain live issue. Strong regulatory science engagement.	National infrastructure, regulatory compliance, EHDS data flows
Asia-Pacific	29% Share	China: 120+ hospitals tracking patient records and drugs. India: blockchain vaccine tracking across 8 states (+32% accuracy). Japan/S. Korea: telemedicine and clinical trial platforms. Medibloc (Korea).	Varying regulatory regimes. China centrally mandated. India pilot-friendly. Singapore emerging as DeSci hub.	Government-mandated deployments, vaccine infrastructure, emerging DeSci
Middle East	Growing	UAE: Guardtime partnership for data privacy; 15 blockchain digital health identity projects launched. Saudi Arabia national health digitization.	Crypto-forward regulatory regimes in UAE/Bahrain. Pro-innovation stance accelerating healthcare pilots.	Digital health identity, remote diagnostics, cross-border payments
Africa / LatAm	Emerging	Rwanda: vaccine monitoring (4 districts), South Africa: drug supply chain (-26% losses), Brazil: pharma counterfeiting pilot (-30% counterfeit instances).	Permissive, often government-sponsored. DeSci adoption high among underfunded researchers using DAO grants for international collaboration.	High social impact, first-mover in underserved data, DeSci equity play

07 Sector Timeline

From Whitepaper to Infrastructure: Key Milestones

2016–2017

Genesis — First Healthcare Blockchain Projects

MediLedger / Chronicled launch pharmaceutical blockchain network (2017). Patientory conducts one of healthcare's first ICOs. Estonia's Guardtime KSI blockchain integrated into national health records. Academic papers proliferate on blockchain EHR potential.

2019–2020

Pilot Era — Consortiums Form

US Drug Supply Chain Security Act (DSCSA) compliance mandate drives pharmaceutical blockchain adoption. IBM Blockchain signs healthcare clients. Health Utility Network (predecessor to Avaneer) forms among major US payers. FDA begins blockchain pilot programs for drug tracking.

2021

DeSci Birth + Enterprise Launch

VitaDAO launches — first major longevity research DAO. Molecule Protocol releases IP-NFT framework. Avaneer Health spins out as standalone company with $50M seed round. COVID-19 vaccine supply chain deployments (WHO, UNICEF) validate blockchain for public health logistics.

2023

Institutional Validation of DeSci

Pfizer Ventures invests $4.1M in VitaDAO — first major pharma investment in a DAO. HairDAO becomes first DAO to file a scientific patent. Bio Protocol BioDAO network hits $200M market cap. Embleema expands virtual clinical trial platform across EU. Avaneer reaches nationwide network coverage.

2024

Binance Labs Enters DeSci

Binance Labs makes first DeSci investment in Bio Protocol (November 2024) — largest institutional signal yet for the sector. GenomesDAO Novartis ALS patient pilot demonstrates 28% faster matching. Pantera Capital leads $10M GenomesDAO round. "DeSci genomic data monetization" searches surge 310% on X and research forums.

2025

NIH Crisis Accelerates DeSci Adoption

7,800+ NIH/NSF grants cancelled ($3B unspent). NIH success rate drops to 19%. 25,000+ science agency staff depart. Approximately 50 active DeSci initiatives documented. Hashed Health v2 network launches (45% faster). Patientory crosses 2M patient records. DeSci market cap hits $1.8B.

2026

Production Infrastructure — Inflection Year

NIH eliminates transparent paylines (January 2026). GENIUS Act passes — first US crypto law enabling tokenized IP frameworks. First stablecoins enter production for international medical transactions. EU EHDS regulation operational. Blockchain healthcare market estimated at $23.1B. AI+blockchain convergence ("DeScAI") formalizes as autonomous research agents enter DeSci stack.

08 Investment Framework

Bull Case, Bear Case & Risk Matrix

Overall Thesis

OW

Overweight vs. Broad Health Tech

Enterprise Layer

7.5/10

Revenue-generating, low vol, long duration

DeSci / Token Layer

6.5/10

High volatility, asymmetric upside

Regulatory Risk

MED

HIPAA/GDPR immutability tension

✦ Bull Case Catalysts

NIH funding collapse creates permanent DeSci tailwind — 50+ active projects in 2026 is just the beginning
GENIUS Act enables legally compliant IP-NFT markets in the US for the first time
First medical stablecoins entering production unlock global cross-border health payment rails
EU EHDS regulation creates a legal secondary-use market for patient data — windfall for Hippocrat, GenomesDAO, and similar projects
Pfizer/Binance Labs institutional validation creates venture LP interest in DeSci token positions
DSCSA full enforcement (2024+) locks in Chronicled/MediLedger as pharmaceutical infrastructure
AI convergence ("DeScAI") dramatically expands what DeSci protocols can automate
Emerging market deployments (Africa, LatAm, South Asia) capture massive underserved populations

✦ Bear Case / Key Risks

GDPR right-to-erasure fundamentally incompatible with blockchain immutability — unresolved legal conflict
Healthcare's legacy IT infrastructure (48% of providers cited incompatibility in 2023) raises integration costs and timelines
DeSci tokens track crypto market cycles more than healthcare fundamentals — bear market risk
Regulatory reclassification of utility tokens as securities could upend DeSci governance structures
Change Healthcare-style cyberattack risk — centralized blockchain nodes remain attack surfaces
Clinical trial delays if FDA does not develop formal blockchain data acceptance framework
VitaDAO/BioDAO research pipelines face same drug development attrition rates (~90% failure) as traditional pharma
Enterprise consortiums (Avaneer) risk political/strategic breakdown among competing institutional members

Investment Vehicle	Access Method	Risk Level	Time Horizon	Key Metric to Watch
Enterprise Blockchain (Avaneer, Guardtime, Chronicled)	Private equity / consortium stakes; indirect via parent equities (IBM, CVS, Aetna)	Low-Med	3–7 years	Network member count, prior auth automation rate, DSCSA compliance volumes
DeSci Blue-Chips (BIO, VITA)	Token purchase on CEX/DEX (Coinbase, Uniswap)	Medium	2–4 years	BioDAO count, IP-NFT royalties distributed, drug candidates in pipeline
Genomics Data Protocols (GenomesDAO, Nebula)	GENE token; early-stage equity (Nebula)	Medium-High	3–5 years	Participant-owned vaults, pharma partnership count, royalty distributions
Early DeSci (HairDAO, AthenaDAO, CryoDAO)	DAO membership + token purchase	High	5–10 years	Patent filings, compound candidates, governance participation rate
DeSci ETF / Index Exposure	Emerging DeSci index products (monitor Bitwise, Grayscale for launches)	Low-Med	2–5 years	Sector AUM inflows, new institutional DeSci fund launches

09 Strategic Outlook

2026–2030: Three Scenarios

Scenario	Probability	Market Size 2030	Defining Catalysts	Investment Implication
Base Case — Steady Institutionalization	55%	$80–120B	DSCSA drives pharma supply chain to near-universal blockchain. Enterprise payer consortiums go live in US and EU. DeSci grows to 200+ active projects. 2–3 IP-NFT-originated drugs enter clinical trials.	Overweight enterprise blockchain equity; core position BIO/VITA tokens (5–8% of crypto allocation)
Bull Case — Regulatory + DeSci Flywheel	30%	$200–276B	FDA formalizes blockchain trial data acceptance. GENIUS Act enables IPO of IP-NFT-originated biotech. NIH funding fails to recover, routing 40%+ of research funding through DeSci by 2029. Stablecoin medical payment rails reach $50B+ volume.	Aggressive DeSci overweight; early positioning in genomic data protocols; seek DAO-to-biotech spinout equity
Bear Case — Regulatory + Integration Stall	15%	$25–40B	GDPR/HIPAA enforcement prevents scalable on-chain health data storage. SEC classifies governance tokens as securities, triggering DeSci project shutdowns. Legacy EHR vendors (Epic, Cerner) build competitive blockchain-adjacent solutions, crowding out startups.	Underweight DeSci tokens; maintain only enterprise consortium equity exposure; reduce allocation to 1–2% of portfolio

Salud Capital View: We assign highest probability to the Base Case but believe the Bull Case probability is higher than consensus reflects. The NIH structural collapse is underappreciated as a DeSci accelerant. The regulatory environment post-GENIUS Act is more constructive than the 2019–2022 period. And the AI+DeSci convergence ("DeScAI") — where autonomous research agents govern on-chain scientific processes — represents a second-order catalyst that most analysts have not yet priced. Position sizing should reflect this asymmetry: 55%+ of the sector allocation in lower-risk enterprise plays, with 30–40% in liquid DeSci tokens sized for the asymmetric upside of the bull case.

10 Salud Capital Watch List

Projects & Developments to Monitor in 2026

Project / Event	Category	Why It Matters	Expected Timeline	Signal Type
Bio Protocol — BioDAO Launchpad v1	DeSci Infrastructure	First structured launchpad for BioDAOs could 10x the number of active projects if successful. Comparable to Y Combinator Demo Day economics.	H1 2026	Bullish Event
VitaDAO — First Drug Candidate Phase I Filing	Longevity / Clinical	First DeSci DAO to advance a compound to Phase I clinical trial would validate the entire BioDAO IP-NFT model at the regulatory level.	2026–2027	Milestone Watch
EHDS Regulation — EU Implementation	Regulatory	EU's European Health Data Space regulation creates the legal framework for secondary health data use — directly enabling data vault protocols (Hippocrat, GenomesDAO) to operate at scale.	2026 Ongoing	Regulatory Catalyst
Medical Stablecoin Production Launch	Global Health / Payments	First stablecoins tailored for cross-border medical transactions entering production (per PMC 2026 Healthcare Predictions). Opens a new $50B+ payments surface.	H1–H2 2026	New Market
Avaneer — Nationwide Network Coverage	Enterprise / Claims	Completion of Avaneer's nationwide prior authorization / eligibility network would mean blockchain-powered claims processing for a significant portion of US insured lives.	2026	Scale Milestone
FDA Blockchain Data Guidance	Regulatory	Formal FDA guidance on blockchain-sourced clinical trial data would unlock Embleema, Hippocrat, and virtual trial platforms to operate at commercial scale with regulatory acceptance.	2026–2027	Watch
GenomesDAO — Pharma Partnership #2	Genomics	Follow-on to Novartis ALS pilot. If GenomesDAO secures a second major pharma partnership for patient matching/recruitment, proves repeatability of the model.	2026	Watch
SEC / CFTC Healthcare Token Guidance	Regulatory Risk	CLARITY Act creates new CFTC/SEC jurisdiction split. Reclassification of DeSci governance tokens as securities would trigger compliance restructuring across most DeSci protocols.	2026–2027	Risk Monitor